Literature DB >> 8373268

Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms.

R S Burd1, R J Battafarano, C S Cody, M S Farber, C A Ratz, D L Dunn.   

Abstract

OBJECTIVE: To determine whether monoclonal antibodies (mAbs) directed against lipopolysaccharide (LPS, endotoxin) act by promoting LPS neutralization, LPS uptake by macrophages, or both processes, the authors assessed the effects of these agents on LPS-induced cytokine secretion and cellular uptake of LPS. SUMMARY BACKGROUND DATA: MAbs directed against LPS have been shown to attenuate LPS-induced macrophage tumor necrosis factor-alpha (TNF-alpha) secretion, a process that may contribute to protective capacity. The mechanisms by which this process occurs have not been established.
METHODS: MAbs directed against LPS were evaluated in vitro for their capacity to (1) inhibit TNF-alpha secretion, and (2) alter fluorescein isothiocyanate-labeled LPS uptake (employing flow cytometry analysis and fluorescence microscopy) by the macrophage-like cell line RAW 264.7.
RESULTS: MAb 8G9, an IgG3 directed against the O-antigen polysaccharide region of Escherichia coli 0111:B4 LPS, significantly reduced LPS-induced TNF-alpha secretion and promoted a more than 40-fold increase in LPS uptake by macrophages. The authors established that this was mediated by a Fc receptor-mediated process because 8G9 F(ab')2 fragments that lack the Fc portion of the IgG molecule were capable of inhibiting TNF-alpha secretion, but did not promote increased LPS uptake to the same degree. Cross-reactive, anti-deep core/lipid A mAb 1B6, an IgG2a, also promoted uptake of E. coli 0111:B4 LPS and O-antigen polysaccharide-deficient E. coli J5 LPS, but only inhibited TNF-alpha secretion induced by E. coli J5 LPS to which it binds most efficiently. MAb 3D10, an IgM also directed against the O-antigen polysaccharide region of E. coli 0111:B4 LPS, inhibited TNF-alpha secretion but did not increase cellular uptake of LPS, presumably acting solely due to LPS neutralization. Polymyxin B, an antibiotic that binds stoichiometrically to the lipid A portion of LPS, inhibited TNF-alpha secretion and prevented cellular LPS uptake.
CONCLUSIONS: These results suggest that IgG and IgM anti-LPS mAbs exert protective capacity by extracellular neutralization of LPS, while IgG Fc receptor-mediated cellular uptake also may serve to bypass macrophage activation and TNF-alpha secretion by promoting internalization and intracellular neutralization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373268      PMCID: PMC1242957          DOI: 10.1097/00000658-199309000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

1.  Protection of mice against lethal endotoxemia by lipid X is mediated through inhibition of neutrophil function.

Authors:  C Lam; E Schütze; H Walzl; E Basalka
Journal:  Circ Shock       Date:  1987

2.  Preparation of F(ab')2 fragments from mouse IgG of various subclasses.

Authors:  E Lamoyi
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  The use of fluorescence quenching in flow cytofluorometry to measure the attachment and ingestion phases in phagocytosis in peripheral blood without prior cell separation.

Authors:  J Hed; G Hallden; S G Johansson; P Larsson
Journal:  J Immunol Methods       Date:  1987-07-16       Impact factor: 2.303

Review 4.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 5.  Manifestations of sepsis.

Authors:  R L Harris; D M Musher; K Bloom; J Gathe; L Rice; B Sugarman; T W Williams; E J Young
Journal:  Arch Intern Med       Date:  1987-11

6.  Stimulation of T-independent antibody responses by hapten-lipopolysaccharides without repeating polymeric structure.

Authors:  R R Skelly; P Munkenbeck; D C Morrison
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

7.  Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate.

Authors:  R M Bannatyne; N M Harnett; K Y Lee; W D Biggar
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

8.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors:  N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance.

Authors:  R S Burd; C S Cody; C S Raymond; D L Dunn
Journal:  Arch Surg       Date:  1993-02

10.  Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody.

Authors:  D L Dunn; W C Bogard; F B Cerra
Journal:  Arch Surg       Date:  1985-01
View more
  4 in total

Review 1.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  N Hiki; D Berger; C Prigl; E Boelke; H Wiedeck; M Seidelmann; L Staib; M Kaminishi; T Oohara; H G Beger
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children.

Authors:  R C M Stephens; K Fidler; P Wilson; G R Barclay; M G Mythen; G L J Dixon; M W Turner; N J Klein; M J Peters
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

4.  Multiple Modes of Action of a Monoclonal Antibody against Multidrug-Resistant Escherichia coli Sequence Type 131-H30.

Authors:  Luis M Guachalla; Katharina Hartl; Cecília Varga; Lukas Stulik; Irina Mirkina; Stefan Malafa; Eszter Nagy; Gábor Nagy; Valéria Szijártó
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.